Jeffrey William Henderson Sells 5,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the sale, the director now directly owns 33,611 shares of the company’s stock, valued at approximately $1,972,629.59. This trade represents a 12.95 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00.

Halozyme Therapeutics Stock Down 2.0 %

Halozyme Therapeutics stock traded down $1.19 during trading on Monday, hitting $57.96. 1,414,542 shares of the company were exchanged, compared to its average volume of 1,294,096. The company has a market capitalization of $7.14 billion, a P/E ratio of 16.90, a PEG ratio of 0.42 and a beta of 1.25. The business’s 50 day moving average is $54.53 and its 200 day moving average is $54.72. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $65.53. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on HALO shares. Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. HC Wainwright raised their price objective on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Finally, Benchmark reiterated a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $62.78.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Halozyme Therapeutics by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,582 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 782 shares in the last quarter. State of Alaska Department of Revenue grew its stake in Halozyme Therapeutics by 7.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 14,838 shares of the biopharmaceutical company’s stock valued at $849,000 after purchasing an additional 995 shares during the period. Nisa Investment Advisors LLC grew its stake in Halozyme Therapeutics by 32.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,495 shares of the biopharmaceutical company’s stock valued at $315,000 after purchasing an additional 1,358 shares during the period. New York State Teachers Retirement System increased its position in shares of Halozyme Therapeutics by 12.8% during the 3rd quarter. New York State Teachers Retirement System now owns 127,327 shares of the biopharmaceutical company’s stock valued at $7,288,000 after purchasing an additional 14,489 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its stake in shares of Halozyme Therapeutics by 173.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,028 shares during the period. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.